Julie Margetta Morgan
Julie Margetta Morgan is currently on a leave of absence. Please contact firstname.lastname@example.org if you need to reach her or a member of her team.
Julie Margetta Morgan in the News
What You Need to Know About ‘ISA’ College Deals, Wall Street Journal
How wiping out $1.5 trillion in student debt would boost the economy, MarketWatch
Measuring the Effects of Loan Forgiveness, Inside Higher Ed
New Rules for the 21st Century: Corporate Power, Public Power, and the Future of Prescription Drug Policy in the United States
Today’s pharmaceutical industry is failing most Americans. Every day, a new story emerges about an outrageous price spike for a lifesaving drug, a fraud perpetrated on the American people in the name of profit, or the revolving door of administration officials entering an agency from a drug company or leaving to go to one—a practice
For decades, regulators have had only limited success in taming a for-profit college industry that routinely defrauds students, inflates prices, and produces devastatingly bad outcomes for student loan borrowers. But recently, instead of promoting complex regulatory schemes, some policymakers have offered a simple solution: take away for-profit colleges’ federal subsidies. Today, Rep. Pramila Jayapal (D-WA)
Student debt cancellation is generating the most online attention out of all of the Democratic presidential candidates’ policy proposals, according to a new analysis. Given that issues like health care or immigration are usually what voters care most about, this is a notable shift. It’s not just the subject of student debt that has captured
By the end of tonight—day two of the first round of the Democratic presidential primary debates—there will be various takes, including who has a better plan to fix health care, who prioritizes the climate crisis, and who’s the most likeable. Here at the Roosevelt Institute, we’re judging the candidates on one essential criterion: How are
In “The Cost of Capture: How the Pharmaceutical Industry Has Corrupted Policymakers and Harmed Patients,” Roosevelt Fellow Julie Margetta Morgan and Advocacy Associate Devin Duffy explore how drug companies influence policymakers and what this means for patients, the American health care system, and our economy. One of a series on Big Pharma, this issue brief
New Rules for the 21st Century: Corporate Power, Public Power, and the Future of the American Economy
America’s political landscape and economic thinking are shifting. The 2016 election—and the rise of powerful movements over the past decade—has shown us that Americans are calling for change. They want a diagnosis of our economy to help make sense of what’s gone wrong and to suggest ways to make things better. In New Rules for
Voters across the political spectrum want policymakers to enact anti-corruption legislation, and Democrats responded by making corruption a signature issue in the 2018 election. This month, they followed through on that promise by introducing the For the People Act, an ethics and government reform package. The bill is the first real movement in Congress on
With outstanding student debt at $1.5 trillion, policymakers and education providers are looking for ways to make college more affordable. Though many argue for enhanced public investment to reduce tuition, others are turning to debt alternatives like income share agreements (ISAs). Through these contracts, universities (often with funding from private investors) contribute to a student’s
To address the $1.5 trillion in outstanding student debt that is held by American borrowers today, it is vital to have a full debate about the costs and benefits of potential solutions. But this debate must be grounded in a solid understanding of the problem. David Leonhardt’s recent takedown of universal student-debt cancellation flows from
The Student Debt Crisis, Labor Market Credentialization, and Racial Inequality: How the Current Student Debt Debate Gets the Economics Wrong
As tuition has risen over the last several decades in the U.S., student loan debt has ballooned. Despite growing debt loads, federal policy encourages the use of loans for financing higher education, based on the assumption that student debt supports increased postsecondary attainment—and, in turn, improved outcomes for individuals and our economy as a whole.
With $1.5 trillion in outstanding student debt, more than 8 million borrowers in default, and millions more delinquent on their repayments, the student loan system today is holding Americans back from economic opportunity and stability. Faced with such troubling trends, Department of Education Secretary Betsy DeVos should be focused on relieving these burdens for borrowers.
The student loan program today serves industry insiders over its core stakeholder: students. The government justifies bailing out these other participants—lenders, servicers, debt collectors, and even colleges—as being in the best interests of students, student loan borrowers, and taxpayers. These claims, however, do not hold up. In Who Pays? How Industry Insiders Rig the Student
Americans today rank corruption of government officials as their top fear—even above fear of North Korea’s use of nuclear weapons. Far from a new phenomenon, public trust in government has polled consistently low for over a decade. Newspapers report daily on elected officials who benefit personally from the policies they pass, regulators who once led